Cipher Pharmaceuticals (TSE:CPH) Issues Quarterly Earnings Results

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) posted its earnings results on Tuesday. The company reported C$0.21 earnings per share (EPS) for the quarter, FiscalAI reports. Cipher Pharmaceuticals had a return on equity of 25.69% and a net margin of 60.82%.The company had revenue of C$17.14 million for the quarter.

Cipher Pharmaceuticals Stock Performance

CPH opened at C$14.11 on Thursday. The business’s 50 day moving average is C$16.63 and its 200-day moving average is C$16.61. The stock has a market cap of C$358.27 million, a PE ratio of 11.86 and a beta of 1.15. The company has a current ratio of 1.25, a quick ratio of 2.67 and a debt-to-equity ratio of 0.32. Cipher Pharmaceuticals has a twelve month low of C$12.48 and a twelve month high of C$20.56.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group set a C$17.00 price target on shares of Cipher Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, Cipher Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of C$17.00.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.